Baxter wins FDA approval for renal therapy solution

SHARE Baxter wins FDA approval for renal therapy solution

A Baxter International Inc. product for use in renal replacement therapy has received approval from the U.S. Food and Drug Administration.

Baxter’s Phoxillum is designed to correct electrolyte and acid-base imbalances for patients undergoing continuous renal replacement therapy. The Deerfield pharmaceutical and medical device maker said it expects the product be available in the U.S. beginning in the second quarter.

“The approval of Phoxillum allows us to offer healthcare providers additional options in managing critically ill acute kidney injury patients treated with CRRT,” said Bruce Culleton, a Baxter vice president and head of its renal therapeutic area.

The Latest
The Hawks have conceded the first goal in eight consecutive games. And after falling 7-2 on Sunday, they’ve now lost seven games in a row. The trends are no coincidence.
Tim Degnan a trusted point man, was key to Richard M. Daley’s political, policy success. As a lawmaker, he raised funds for the new Comiskey Park to keep the White Sox in Chicago.
“Fuentes is among the most prominent and unapologetic antisemites around,” David Goldenberg, the Anti-Defamation League director of the Midwest regional office, told the Chicago Sun-Times on Sunday.
The Bears’ very, very bad day started with quarterback musical chairs and went down from there.